Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against Myriad Genetics, Inc. (MYGN) after the company reported significantly lower-than-expected Q2 2026 revenue and drastically cut its full-year 2026 guidance. This announcement followed Myriad Genetics reiterating stronger guidance just three months prior, leading to a stock price drop. The firm encourages affected investors to contact them to assist with the investigation.